You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History III1 Apr 2017PD47-04 STATIN USE, SERUM LIPID LEVELS AND PROSTATE INFLAMMATION; RESULTS FROM THE REDUCE STUDY Emma Allott, Lauren Howard, Adriana Vidal, Daniel Moreira, Ramiro Castro-Santamaria, Gerald Andriole, and Stephen Freedland Emma AllottEmma Allott More articles by this author , Lauren HowardLauren Howard More articles by this author , Adriana VidalAdriana Vidal More articles by this author , Daniel MoreiraDaniel Moreira More articles by this author , Ramiro Castro-SantamariaRamiro Castro-Santamaria More articles by this author , Gerald AndrioleGerald Andriole More articles by this author , and Stephen FreedlandStephen Freedland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2364AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Statin use is associated with lower risk of advanced prostate cancer, but mechanisms are not completely understood. In addition to cholesterol-lowering, statins also have systemic anti-inflammatory properties, but the effect of serum cholesterol levels and statin use on benign prostate inflammation has not been explored. The aim of this study was to examine associations between serum lipid levels, statin use, and histological prostate inflammation among men with a negative prostate biopsy. METHODS We conducted a retrospective analysis of data from 6,655 men with a negative baseline prostate biopsy in the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Statin use and serum lipid levels [total cholesterol, low and high density lipoprotein (LDL and HDL, respectively), triglycerides] were assessed at baseline. Prostate inflammation was classified as chronic (lymphocytes, macrophages) or acute (neutrophils) following central histological review of negative baseline prostate biopsies. Multinomial logistic regression was used to examine the effect of serum lipid levels and statin use on presence and extent of chronic and acute prostate inflammation [none, moderate (<20% biopsy cores), severe (≥20% biopsy cores)], adjusting for potential confounders. RESULTS Chronic and acute prostate inflammation was found in 5,152 (77%) and 1,005 (15%) men, respectively. Serum lipid levels were not associated with presence or extent of chronic prostate inflammation. Total cholesterol, LDL and triglycerides were not associated with presence or extent of acute prostate inflammation. However, men with high HDL (≥60 vs. <40 mg/dl) had reduced presence of any acute inflammation (OR 0.79; 95% CI 0.63-0.99), and were less likely to have severe acute inflammation (OR 0.66; 95% CI 0.45-0.97). Statin users had reduced presence of any chronic prostate inflammation (OR 0.81; 95% CI 0.69-0.95), and were less likely to have severe chronic inflammation and severe acute inflammation (OR 0.80; 95% CI 0.68-0.95 and OR 0.73; 95% CI 0.53-1.00, respectively), relative to non-users. CONCLUSIONS In a cohort of men with a negative prostate biopsy, those with high HDL had lower presence and extent of acute prostate inflammation and statin users had reduced presence and extent of chronic inflammation. These findings support an effect of HDL and statin use on benign prostate inflammation. As we have shown inflammation is correlated with prostate cancer risk, this work suggests a mechanism linking serum lipid levels, statins and prostate cancer risk. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e897 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Emma Allott More articles by this author Lauren Howard More articles by this author Adriana Vidal More articles by this author Daniel Moreira More articles by this author Ramiro Castro-Santamaria More articles by this author Gerald Andriole More articles by this author Stephen Freedland More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract